Stage
No active trials
Next date
None yet
Trials
0 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Thyroid Eye Disease
- Main trialPhase 1
- “The investigational drug, ZB001 is a humanized IgG1κ monoclonal antibody (mAb) targeting human IGF-1R. This clinical trial will examine the safety, tolerability, and pharmacokinetics (PK) of single ascending doses of ZB001 in healthy Chinese subjects.”In the company’s words, NCT05542303 on ClinicalTrials.gov
Other drugs for Thyroid Eye Disease
- IBI311Innovent · Phase 3
- MHB018AMinghui Pharmaceutical (Hangzhou) Ltd · Phase 3
- ZL-1109Zai Lab (Shanghai) Co., Ltd. · Phase 3
- KHN939Beijing Kanghong Biological Medicine Co., Ltd. · Phase 3
- LinsitinibSling Therapeutics, Inc. · Astellas · Phase 3
- TeprotumumabAmgen · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Completed | 4 Apr 2023 | A Safety, Tolerability and Pharmacokinetics Study of ZB001 in Healthy Subjects | |
| Phase 1Completed | 17 Apr 2024 | Study of ZB001 in Chinese Patients With Thyroid Eye Disease |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026